L42 -Insulin and anti-diabetic agents Flashcards

(52 cards)

1
Q

List some complications of hyperglycemia and hypoglycemia?

A

Hyper = nephropathy, neuropathy, retinopathy, stroke, gangrene, heart attack

Hypo = fatigue, nausea, dizziness, coma, confusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define the spectrum of type I DM?

A
  • Type 1 IDDM
  • Type 1.5 latent autoimmune diabetes of adulthood (LADA)
  • Type 1B – idiopathic diabetes
  • Maturity onset diabetes of young: single gene mutation (MODY)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Briefly define the cause of IDDM and NIDDM?

A

IDDM = Autoimmune disease that causes pancreatic islet cell destruction = lack of insulin production

NIDDM = combined defect of insulin secretion and insulin resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Treatment strageties for Type 1, 2 DM and GDM?

A

Type 1 = Diet, exercise, Insulin-dependent

Type 2 = Diet, exercise, Anti-diabetic drug, Insulin (1/3)

GDM = Diet, Insulin, Anti-diabetic drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which insulin precursors are used to evaluate insulin function?

A

Preproinsulin = signal sequence + C peptide = determine ability to secrete insulin

Proinsulin and C peptide = determine dynamic range of B cell function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the 24-h physiological insulin secretion trend?

A

almost identical to 24-hour glucose profile

|&raquo_space; admin of exogenous insulin should mimic the pattern of endogenous insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Compare basal and bolus insulin admin.?

A

1) Basal insulin: Mimics normal pancreatic basal insulin secretion
- Long lasting
- Smooth, peakless to avoid hypoglycaemia

2) Bolus insulin: Give before meals
- Short duration
- Avoid
hypoglycaemia

Both predictable and reproducible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

List 4 principal types of insulin prearation based on acting time?

A

– Short acting : Regular human insulin (Humulin®, Novolin®)

– Rapid onset and ultrashort-acting: Insulin Lispro and Insulin Aspart

– Intermediate acting: protamine (NPH) and lente

– Long acting : Insulin Glargine, Insulin Detemir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain how regular human insulin/ Humulin®/ Novolin® extends it’s onset and duration of action?

A

1) self-aggregate in antiparallel fashion to form active dimers
2) stabilize around Zn2+ = inactive hexamers = cannot bind to insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Indications for regular human insulin injection? Define the onset and acting time?

A

Short onset: 30min, peak 1-2h

Short acting: 5-8h

Bolus injection for diabetic ketoacidosis, Changing insulin requirements (e.g. infection, post-op)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Give 4 limitations of regular human insulin?

A
  • Inconvenient admin. before meal
  • Risk of hypoglycaemia if delayed meal
  • Mismatch with postprandial hyperglycaemia peak
  • Late postprandial hypoglycaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the structure of insulin Lispro?

A

Anti-aggregation: Reverse the 2 amino acids (Proline 28, Lysine 29) at C-terminal of B-chhain

> > prevents hexameric formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define the onset and acting time of Insulin Lispro. Give one advantage?

A
  • Rapid onset = 10-15 min (taken just before meal)
  • Ultrashort acting = 2-4h
  • Peak effect 30-60 min

Mimics endogenous insulin secretion = improves postprandial glucose control without risk of hypoglycemia between meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the structure of Insulin Aspart?

A

Substitute the B-chain proline 28 with aspartic acid

|&raquo_space; rapidly breaks into biologically active monomer after subcutaneous injectio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Define the onset and acting time of Insulin Aspart?

A

 Rapid onset (10-20 min)

 Ultrashort acting: 2-4 hours

 Peak effect: 1 hour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name 2 intermediate acting insulin.

A

 Protamine (NPH) insulin

 Lente insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the structure of Protamine (NPH) insulin and Lente insulin

A

Neutral protamine Hagedorn (NPH) insulin = mixture of insulin + protamine

Lente insulin = mixture of 30% semilente + 70% ultralente insulin (very insoluble, delayed onset and prolonged duration of action)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Define the onset and acting time of NPH insulin?

A

Insulin bound to protamine slowly dissolves

Intermediate onset: peak 4-10h
Intermediate acting: 10-18h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Define the onset and acting time of Lente insulin?

A

Zinc-bound insulin slowly dissolves:

Intermediate onset: peak 4-10h
Intermediate acting: 10-18h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Name 2 long-acting insulin?

A

Insulin Glargine (Lantus)

Detemir Insulin (Levemir)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe the structure and MoA of Insulin Glargine?

A
  1. Attach 2 arginines to the B chain c-terminal
  2. Substitute asparagine with glycine at A21 (A chain)

Isoelectric point shifted to pH 7.0 (close to body pH)

> > precipitates in the subcutaneous milieu&raquo_space; stabilizes insulin hexamers
slow, consistent absorption into systemic circulation

22
Q

Describe the structure and MoA of Detemir Insulin?

A
  1. Add myristic acid (FA) to lysine at position B29
  2. Omit threonine in position B30

fatty acid causes it to bind to albumin
» slow release, extended circulating life

23
Q

Define the acting time of Insulin Glargine and Detemir insulin?

A

Insulin Glargine = Ultra-long-acting (maximum activity maintained for >=24 hours)

Detemir insulin = Long acting, 23 hours

24
Q

List some complications of insulin therapy?

A
  1. Hypoglycemia: confusion, weakness, coma…
  2. Insulin allergy, immune resistance
  3. Lipodystrophy at injection sites (use multi-site injection)
  4. Abuse: Development of type 2 diabetes + lifetime dependency
25
List 2 classes and examples of insulin secretogogues?
Sulfonylureas: - 1st gen = chlorpropamide, tolbutamide - 2nd gen***** = glipizide, glimepiride, glibenclamide Non-sulfonylureas: - meglitinide analogs: repaglinide, nateglinide
26
MoA of sulfonylureas?
1) Bind extracellularly to a high-affinity receptor 2) close the associated inward rectifier ATP-sensitive K+ channel in pancreatic β-cell 3) membrane depolarization >> opens voltage-gated Ca2+ channel 4) Ca2+ entry >> exocytosis of insulin secretion
27
Indication and resistance of Sulfonylureas?
- Type 2 patients with residual β-cell function - adjunctive to nutritional, exercise therapy Primary failure = 1/4 fail to respond Secondary failure = lose response over time
28
Define the acting time and ADR of Sulfonylurea?
Long duration of action (12-48 hours) - Weight gain: increase appetite, decrease glucose excretion - Hypoglycaemia - GI disturbances, Rashes - Cross placenta and deplete fetal insulin
29
MoA and indication of Non-sulfonylureas/ Meglitinide analogs?
At functioning pancreatic β cells: - Bind to a distinct site on sulfonylurea receptor of ATP-sensitive K+ channels>> very rapid, transient insulin secretion - Control post-prandial glucose
30
Indication and onset and acting time of Meglitinide analogs?
controlling postprandial glucose  Rapid onset  Short duration of actions (~2 hours)
31
ADR of Meglitinide analogs?
 Hypoglycemia (incidence much lower than sulfonylureas)  Weight gain
32
Name one class of Incretin mimetics and give 2 examples
Glucagonlike peptide (GLP) analogues/agonist: exenatide (GLP-1 agonsit), liraglutide (GLP-1 analog)
33
MoA of Incretin mimetics?
Analogues of endogenous incretins: GI hormones secreted after food ingestion: Include glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP) >> stimulate glucose-dependent insulin secretion from B-cell + glucagon release from alpha cell
34
Describe the endogenous degradation of Incretins?
rapidly degraded by dipeptidyl peptidase-4 (DPP-4)
35
Describe the structure of incretin mimetics to resist DDP-4 degradation?
Exenatides = only 53% homology with GLP = decrease degradation by DPP-4 Liraglutide = fatty acid chain added, complex binds to albumin = decrease degradation by DPP-4
36
Indication of incretin mimetics? ADR?
Exenatide = Type 2 DM, decrease appetite and gastic emptying, WEIGHT LOSS***** Liraglutide = WEIGHT LOSS***** ADR: GI disturbances, Dizziness, Headache
37
Name 2 DDP-4 inhibitor and MoA?
Dipeptidyl peptidase-4 (DPP-4) inhibitors / incretin enhancers Sitagliptin, vidagliptin inhibit DPP-4-mediated degradation of active GLP-1 >> increase insulin secretion
38
Indication and ADR of DDP-4 Inhibitor?
monotherapy / combination therapy for long term glucose control ADR: URTI***, Sore throat***, Diarrhea
39
Name 2 insulin sensitizers?
Biguanides (metformin) Thiazolidinediones: rosiglitazone , pioglitazone
40
MoA of Metformin?
1) Activating AMP-activated protein kinase (AMPK) in liver: a) ↓ gluconeogenic genes (PEPCK, G6Pc) to decrease glucose production b) ↓ fatty acid synthesis, ↑ fatty acid oxidation 2) Modulates gut microbiota
41
Indication of Metformin? C/O?
- Obese with insulin resistance - Lower CVD complications - Decrease DM-related cancers C/O: - Renal, hepatic diseases, Alcoholism, Severe Infection
42
ADR of Metformin?
GI disturbances metformin- associated lactic acidosis (MALA) Long-term use = vitamin B12 deficiency
43
MoA of Thiazolidinediones (rosiglitazone,pioglitazone) ?
insulin-sensitizing drugs: bind to peroxisome proliferator-activated receptor γ (PPARγ, nuclear hormone receptor) in adipose tissue (fat), muscle, liver 1) decrease insulin resistance 2) anti-inflammatory effects 3) Improve lipid profiles
44
Indication, risks and ADR of Thiozolidinediones?
prevention of type 2 diabetes Risks: - Rosiglitazone > heart attack - Bladder cancer (Pioglitazone) ADR: weight gain, fluid retention
45
Name 2α-Glucosidase inhibitors ?
Acarbose | Miglito
46
MoA of α-Glucosidase inhibitors ?
Competitive inhibitor of α-glucosidase >> block postprandial digestion, absorption of starch, disaccharides from small intestine >> inhibits glucose absorption
47
Indication of α-Glucosidase inhibitors ?
Combo therapy to control glucose Weak anti-diabetic effect, no hypoglycaemia No effect on body weight
48
ADR of α-Glucosidase inhibitors ?
Not absorbed into the bloodstream Local GI ADR:  Flatulence  Diarrhoea  Abdominal pain/cramp
49
Name 2 Sodium glucose transporter protein-2 (SGLT2) | inhibitors?
Dapagliflozin Canagliflozin
50
MoA of SGLT-2 inhibitors?
Act on kidney (proximal tubule): Decrease active glucose reabsorption >> increase urinary glucose excretion
51
Indication of SGLT-2 inhibitors? ADR?
Decrease CVD mortality and morbidity Control Type 2 DM  Genital infection  Polysuria
52
Which anti-diabetic drug can cause MALA? Explain the mechanism.
Metformin: Metformin-asso.-lactic-acidosis: rare, fatal Inhibition of Pyruvate dehydrogenase, mitochondria transport of reducing agents >> Enhance anaerobic metabolism >> turn pyruvate into lactate